Trombocitopenia Aguda Severa Asociada Al Uso De Tirofiban Posterior a Intervención Coronaria Percutánea: A Propósito De Un Caso

Abstract

espanolLa terapia antiplaquetaria en el manejo de paciente con enfermedad coronaria ha cambiado en los ultimos anos, ya que se han introducido al mercado farmacos nuevos y mas potentes como los inhibidores de la glicoproteina IIB/IIIA que se utilizan por hemodinamistas en aquellos pacientes con alta carga trombotica, sin embargo, estos medicamentos no son inocuos y se pueden presentar eventos adversos asociados a los mismos, el tirofiban no es la excepcion a la regla. En el siguiente reporte se comenta el caso de un paciente sin antecedentes de patologia hematologica, no plaquetopenia previa, quien ingresa a sala de hemodinamia por sindrome coronario cronico con indicacion de angioplastia, hemograma de ingreso con plaquetas en rango de normalidad, despues de 12 horas de infusion con tirofiban en control de hemograma plaquetopenia severa con score 4T para HIT (Trombocitopenia inducida por heparina) de baja probabilidad EnglishAntiplatelet therapy in the management of patients with coronary artery disease has changed in recent years, as new and more powerful drugs such as glycoprotein IIB/IIIA inhibitors that are used by hemodynamicists in highburden patients have been introduced to the market. thrombotic, however, these drugs are not safe and associated adverse events may occur, tirofiban is not the exception to the rule. The following report discusses the case of a patient with no history of hematological pathology, no prior platelet penia, who is admitted to the hemodynamics room due to chronic coronary syndrome with indication for angioplasty, admission hemogram with platelets in the normal range, after 12 hours of infusion with tirofiban in control of hemogram severe plaquetopenia with score 4T for HIT (Heparin-induced thrombocytopenia) of low probability.